CANCER

Immunology

Stem Cells

Cell Death

Neurodegeneration

Cellular Stress

Inflammation

Proteasome

Diabetes

View All Physiological Processes & Diseases

Diabetes is a disease characterized by either the inability to produce enough insulin or a lack of cellular response to insulin. The resulting high blood sugar levels lead to myriad health issues including cardiovascular disease, vision loss, nerve damage, and kidney disease. Current therapies for glycemic control include metformin, sulfonylureas and PPAR-γ agonists. Newer modalities targeting the incretin axis include dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. A novel method for controlling glucose via the kidneys is inhibition of sodium glucose co-transporter 2 (SGLT2).

Adipogenesis

A-769662

Potent and reversible AMPK allosteric activator that inhibits fatty acid biosynthesis

Fatostatin

Fatostatin blocks adipogenesis by inhibiting the activation of SREBP

GSK

Alsterpaullone

Alsterpaullone is a potent inhibitor of GSK-3β

CHIR-99021

Potent and selective inhibitor of GSK-3β

SB-216763

Potent and selective inhibitor of GSK-3α/β

AMPK

Dorsomorphin

Potent and selective inhibitor of AMPK

AICAR

AICAR is an activator of AMPK

Metformin

Inhibits gluconeogenesis by activating the AMPK pathway

PPAR

Rosiglitazone maleate

Clinically useful PPARγ agonist

Pioglitazone HCl

Clinically useful PPARγ agonist

Diabetes

New Products

BIOCHEMICAL TARGETS

Processes and Diseases

CUSTOM SYNTHESIS

CHEMICAL LIBRARIES

FOCUS NEWS:

Update on the Latest Anti-SARS-CoV-2 Molecules

The emergence of SARS-CoV-2 has precipitated an unprecedented effort by the scientific community to find and develop potential therapeutics and vaccines for this new virus to halt the ongoing pandemic’s onslaught. Fortunately, the SARS-CoV-2 genome is highly...

Focus BiomoleculesPlymouth Meeting, PA USA1-855-FOCUS21

®Copyright 2020 Focus Biomolecules. All Rights Reserved. Site by A.N. Creative